Sugi Predict

Sugi Predict / Compounds / SCHEMBL30880886

SCHEMBL30880886

SCHEMBL30880886

CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)C(C)C)[C@@H](C)O

nearest known ligand 0.61

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ IL23R Q5VWK5 16/20 0.61
▸ GLP1R P43220 2/20 0.57
▸ MAGI3 Q5TCQ9 1/20 0.57
▸ KISS1R Q969F8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30578727 0.94 IL23R (0.62) IL23RMAGI3KISS1R
SCHEMBL29597475 0.92 IL23R (0.61) IL23RKISS1R
SCHEMBL30880899 0.89 GLP1R (0.63) GLP1R
SCHEMBL29523517 0.89 PRMT1 (0.66) IL23RGLP1RMAGI3
SCHEMBL30567715 0.88 GLP1R (0.62) IL23RGLP1RKISS1R
SCHEMBL30471720 0.87 OPRM1 (0.65) IL23RKISS1R
SCHEMBL30906378 0.86 CCKBR (0.67) IL23RGLP1R
SCHEMBL31683321 0.86 PRMT1 (0.62) IL23RGLP1RMAGI3KISS1R
SCHEMBL29522786 0.86 PRMT1 (0.62) IL23RGLP1RMAGI3KISS1R
SCHEMBL30946947 0.85 KISS1R (0.64) MAGI3KISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570729-B2 Antibody fragment based antifungal conjugate selectively targeting candida ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) 2026-03-10 — — US disclosed
US-20240092878-A1 AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) 2024-03-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570729-B2 Antibody fragment based antifungal conjugate selectively targeting candida SERPINH1, HM13, NGLY1 IL23R 2925/4885GLP1R 2596/4885MAGI3 3133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback